AbbVie Inc. (ABBV) stock prices updated...
 

AbbVie Inc. stock price

AbbVie Inc. latest news:


  • 09/18/2017 09:52:02

    BRIEF-AbbVie announces positive topline results from phase 3 trial evaluating Venclexta/Venclyxto tablets in combination with Rituxan

    * AbbVie announces positive topline results from phase 3 trial evaluating Venclexta™/Venclyxto™ (Venetoclax) tablets in combination with Rituxan® (Rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic Leukemia

  • 09/11/2017 09:17:10

    AbbVie says deaths in arthritis trial not linked to drug

    AbbVie Inc(ABBV) said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.

  • 09/11/2017 09:16:49

    UPDATE 2-AbbVie says deaths in arthritis trial not linked to drug

    Sept 11 (Reuters) - AbbVie Inc said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.

  • 09/04/2017 00:24:38

    BRIEF-Inventiva and AbbVie extend agreement

    INVENTIVA SA: * INVENTIVA AND ABBVIE EXTEND AGREEMENT TO DISCOVER NEW POTENT ORALLY-AVAILABLE SMALL MOLECULE RORΓ INVERSE AGONIST DRUG CANDIDATES.

  • 07/31/2017 00:23:17

    REFILE-BRIEF-AbbVie to delist from Euronext Paris

    * This request has been approved by the Board of Directors of Euronext Paris SA

  • 07/28/2017 14:28:40

    AbbVie's drug for all types of hepatitis C wins EU approval

    July 28 (Reuters) - AbbVie Inc said on Friday it had received European approval to market its drug for treatment of all six major forms of hepatitis C.

  • 07/28/2017 09:10:26

    AbbVie Slips Despite Q2 Earnings Beat


  • 07/28/2017 05:56:31

    AbbVie shares surge 2% on Q2 profit, revenue beats

    AbbVie Inc. shares surged 2% in premarket trade Friday after the company reported second-quarter profit and revenue beats. Earnings for the latest quarter rose to $1.92 billion, or $1.19 per share, from $1.61 billion, or 98 cents per share in the year-earlier period. Adjusted earnings-per-share were $1.42, compared with the FactSet consensus of $1.40. Revenue rose to $6.94 billion from $6.45 billion, compared with the FactSet consensus of $6.93 billion. Revenue for anti-inflammatory Humira came in at $4.72 billion, above the FactSet consensus of $4.64 billion. Revenue for cancer drug Imbruvica came to $626 million, above the FactSet consensus of $608 million. Revenue for the Hepatitis C therapy Viekira came in at $225 million, below the FactSet consensus of $251 million. Revenue for the therapy Lupron, which is used to delay the onset of puberty, came in above the FactSet consensus, and revenue for digestive drug Creon came in just below the FactSet consensus. The company also confirmed its 2017 EPS and adjusted EPS guidance. AbbVie shares have surged 8.8% over the last three months, compared with a 3.8% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Abercrombie & Fitch CompanyANF | Aberdeen Greater China FundGCH | Aberdeen Japan Equity FundJEQ | Aberdeen Singapore FundSGF | ABM Industries IncorporatedABM | Acadia Realty TrustAKR | Accenture plc.ACN | Acco Brands CorporationACCO | Accuride Corporation NewACW | Ace LimitedACE |